Literature DB >> 2517000

Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.

G Steinkamp1, B Tümmler, R Malottke, H von der Hardt.   

Abstract

To test whether early treatment could postpone the chronic colonisation of the respiratory tract with mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, we performed a pilot study in 28 patients aged 2 to 18 years. A two week course of azlocillin (150 mg/kg/day) and tobramycin (10 to 15 mg/kg/day) was given after a mean duration of P aeruginosa colonisation of five months (range one to 11 months). Weight for height increased significantly by 3.5% (SEM 0.7%) of the predicted normal after chemotherapy. The eradication of P aeruginosa that was achieved in 18 children directly after hospital treatment was only temporary. Samples from only 10 and five patients remained negative three and six months after treatment, respectively. Five children remained free from P aeruginosa for a prolonged period of 14 to 32 months. We conclude that, apart from the clinical improvement in all patients, some children might benefit from early antipseudomonas treatment with respect to the bacteriological outcome. Most children, however, experience only a temporary reduction in colonisation. Further investigations in form of controlled clinical trials seem justified.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517000      PMCID: PMC1792706          DOI: 10.1136/adc.64.7.1022

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

Review 4.  Why is Pseudomonas the colonizer and why does it persist?

Authors:  R Ramphal; S Vishwanath
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

5.  Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis.

Authors:  R Gold; S Carpenter; H Heurter; M Corey; H Levison
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

6.  Revised pyocin typing method for Pseudomonas aeruginosa.

Authors:  J A Fyfe; G Harris; J R Govan
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

7.  Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Authors:  M Szaff; N Høiby; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1983-09

8.  Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.

Authors:  P Kubesch; M Lingner; D Grothues; M Wehsling; B Tümmler
Journal:  Scand J Gastroenterol Suppl       Date:  1988

Review 9.  Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis.

Authors:  J R Govan; G S Harris
Journal:  Microbiol Sci       Date:  1986-10

10.  Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

Authors:  P H Beaudry; M I Marks; D McDougall; K Desmond; R Rangel
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

View more
  9 in total

Review 1.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

2.  IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  S M Cordon; J S Elborn; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

Review 3.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

4.  Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.

Authors:  B Tümmler; U Koopmann; D Grothues; H Weissbrodt; G Steinkamp; H von der Hardt
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

Review 5.  Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.

Authors:  Federico Marchetti; Luisella Giglio; Manila Candusso; Dino Faraguna; Baroukh M Assael
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

6.  Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  E F Marley; C Mohla; J M Campos
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

Review 7.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Simon C Langton Hewer; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-04-25

Review 8.  Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.

Authors:  Rashmi Ranjan Das; Sushil Kumar Kabra; Meenu Singh
Journal:  ScientificWorldJournal       Date:  2013-12-30

Review 9.  Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Authors:  Cordula Koerner-Rettberg; Manfred Ballmann
Journal:  Core Evid       Date:  2014-09-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.